For how we live.
Two pragmatic randomised trials and a Medicare nursing home cohort landed in the same week. Together they show real protection against hospitalisation and a durability question nobody has answered.
In 2,292 hip fractures across six cities in Nagano, snowfall raised the odds of admission — until the models adjusted for how cold it was, at which point the association disappeared.
Reanalyzed EEG data from a phase 3 trial finds lemborexant and zolpidem leave distinct signatures on sleep architecture. Only the slow-oscillation increase predicted less insomnia severity.
A network meta-analysis of 41,084 surgical patients over 60 ranked 52 drug interventions. Dexmedetomidine held up after high-risk trials were excluded; almost nothing changed length of stay or mortality.
Standard questionnaires found no daytime difference between suvorexant and placebo. Four-times-daily smartphone prompts found fatigue worse in the morning and better later. The trial had 40 people.
In 311 adults aged 55 to 95, remission rates were 40% and 51% in the two intervention arms at one year, against 16% for online patient education. Adding human support helped a little.